ABCG1 and familial hyperaldosteronism: We found that in FH patients PCSK9-i therapy significantly enhanced the ABCG1 and the aqueous diffusion-mediated HDL-CEC, while it significantly reduced serum CLC, a marker of serum proatherogenic potential, linked to an enhanced CV risk (Adorni et al., 2019b).